# Verici Dx expands kidney transplant research through US clinical trial agreement

- Link: https://www.directorstalkinterviews.com/verici-dx-expands-kidney-transplant-research-through-us-clinical-trial-agreement/4121268311
- Published: 2026-10-29T12:27:00+00:00
- Author: Amilia Stone

[Verici Dx](https://www.directorstalkinterviews.com/company/verici-dx-plc/vrci.l)
has secured an order from Asahi Kasei Therapeutics to provide blood-based biomarker
testing for a Phase 2 clinical trial investigating pegrizeprument, adding a new 
application for its molecular diagnostic technology in kidney transplantation research.

The agreement will see Verici Dx provide testing that includes its predictive transplant
rejection assay (PTRA) as an exploratory research tool. The work is intended to 
help researchers understand biological responses to treatment and investigate factors
that may influence outcomes following kidney transplantation.

The study will assess pegrizeprument, an investigational immunosuppressive therapy
being developed for the prevention of acute rejection in solid organ transplant 
recipients. Verici Dx’s role will be to provide molecular biomarker analysis to 
support the research programme. The financial value of the order has not been disclosed,
and the testing is intended for exploratory research rather than routine clinical
decision-making.

The agreement reflects the potential for transplant diagnostics to contribute to
pharmaceutical research and development. By examining biological signals in blood
samples, researchers can investigate how patients respond to treatment and whether
particular molecular patterns are associated with transplant outcomes. Such findings
may help inform future research into more personalised approaches to post-transplant
care, although the clinical significance of any results will need to be established
through further studies.

Verici Dx’s PTRA assay is part of its wider diagnostic offering for kidney transplantation.
The company is developing blood-based tests designed to assess biological responses
and the risk of transplant rejection. Its Tutivia test is intended to assess the
risk of acute rejection following a kidney transplant, providing clinicians with
additional information to support patient management.

The company has also welcomed the launch of the US Department of Health and Human
Services’ 2026 Kidney Care National Plan. The initiative focuses on preventing kidney
failure, improving dialysis care and reforming transplantation.

_**[Verici Dx Plc](https://www.directorstalkinterviews.com/company/verici-dx-plc/vrci.l)**(
LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests
forming a kidney transplant diagnostics platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient outcomes._

Share on:
